Roche Holding AG (RHO F) stock market data APIs
€362.0306
-3.09(-0.9%)
as of June 17, 2026
Try our APIs with
free plan!
Roche Holding AG Financial Data Overview
Price chart is built with
Anychart
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Prev. Close
362.0306
Open
358.938
High
365.1388
Low
358.411
52 wk Range
261.6097-404.7108
Market Cap
288 014 M
P/E Ratio
20.7807
Shares Outstanding
107 M
Revenue
63 356 M
Dividends (Yield)
0.0271
Beta
0.326
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Roche Holding AG data using free add-ons & libraries
Get Roche Holding AG Fundamental Data
Roche Holding AG Fundamental data includes:
- Net Revenue: 63 356 M
- EBITDA: 24 044 M
- Earnings Per Share: 17
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG News
New
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02
H.C. Wainwright notes that Roche’s (RHHBY) persevERA trial “disappointingly” failed, though the firm does not view the frontline opportunity as eliminated for palazestrant and does not believe t...
Once a Hot Stock-Market Trend Has a Name, Its Best Days Are Likely Past
Still, new research finds that for named trends such as FAANG and the Magnificent Seven, market-beating returns can last for about a year. Continue reading
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
F. Hoffmann-La Roche Ltd Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as y...
Novartis, Roche’s Food Allergies Treatment Xolair Gets FDA Approval
Novartis and Roche Holding said the U.S. Food and Drug Administration approved their Xolair treatment to reduce allergic reactions following the exposure to one or more foods. Continue reading
Get Roche Holding AG fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
